Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7

DUBLIN, Dec. 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 37^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Monday, January 7, 2019 at 10:30 a.m. PST / 6:30 p.m. GMT. 

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at .  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at .

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these therapeutic areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase®, Defitelio® (defibrotide) and Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S.  For country-specific product information, please visit .  For more information, please visit  and follow us on Twitter at .

View original content to download multimedia:

SOURCE Jazz Pharmaceuticals plc